News

The National Institute of Allergy and Infectious Diseases of the US National Institute of Health has awarded a contract for process development and formulation of the NXT-2 Pan Fungal Vaccine to begin in 2024.  This is a critical milestone in the development of the NXT-2 vaccine for invasive fungal infections.

https://scienmag.com/breakthrough-vaccine-targets-multiple-fungal-infections/   NXT-2 successfully protects against and treats vaginal yeast infections in mice, according to a newly published study in Nature Vaccines.

This is the newest application of the vaccine, which was previously shown to protect against the three most common fungal pathogens in four preclinical animal models, including nonhuman primates. These three fungi are responsible for more than 80% of fatal fungal infections.

In the 35.5 million inpatient visits documented in 2018 in the US, approximately 666 235 fungal infections were diagnosed, with an estimated attributable cost of $6.7 billion. Aspergillus, Pneumocystis, and Candida infections accounted for 76.3% of fungal infections diagnosed, and 81.1% of associated costs. Most fungal disease occurred in patients with elevated risk of infection. The visit costs, lengths of stay, and risks of mortality in this population were more than twice that of those without fungal diagnoses. A further 6.6 million fungal infections were diagnosed during outpatient visits.